Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Neurology and Therapy|March 24, 2025
Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with SchizophreniaItay Perlstein, Avia Merenlender Wagner, Anna Elgart, et al.
Clinical Pharmacology in Drug Development|March 4, 2022
Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of RisperidoneItay Perlstein, Avia Merenlender Wagner, Roberto Gomeni, et al.
Human Gene Therapy|June 28, 2003
The incorporation of an ion channel gene mutation associated with the long QT syndrome (Q9E-hMiRP1) in a plasmid vector for site-specific arrhythmia gene therapy: in vitro and in vivo feasibility studiesDenise Y Burton, Cunxian Song, Ilia Fishbein, et al.
Neurology and Therapy|October 26, 2025
Population Pharmacokinetic-Based Strategies for Switching Patients with Schizophrenia Between Long-Acting Injectable Formulations of Risperidone: R064766 or RBP-7000 to TV-46000Itay Perlstein, Jonathan Meyer, Sharath Kumar, et al.
CNS Drugs|June 15, 2026
A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous UseAvia Merenlender Wagner, Itay Perlstein, Pavel Farkas, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 18, 2006
Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonistDennis L Sprecher, Christine Massien, Greg Pearce, et al.
Clinical Drug Investigation|February 3, 2026
Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective DisorderIrina Cherniakov, Avia Merenlender Wagner, Roy Eshet, et al.
Pageof 2